More than 140,000 genetic mutations have been linked to cancer, but there are only a few dozen approved targeted therapies. A prominent businessman has taken up the challenge to find new targeted therapies by endowing a research fund in cancer drug discovery. Ronald James, president and CEO of James Marine, Inc., established the James Family [...]
News: November, 2013« Previous Page
M y cancer story is not unique, not special in any way. But telling my story is a form of therapy for me—a way to exorcise some of the less pleasant details of an unexpected journey and exalt some important things I learned along the way.
Arteaga to lead major new cancer research initiatives Carlos Arteaga, M.D., Donna S. Hall Professor of Breast Cancer, has been appointed to lead two newly created cancer research initiatives at the Vanderbilt-Ingram Cancer Center. He has been named the founding director of the Center for Cancer Targeted Therapies (CCTT) and director of the Vanderbilt-Ingram Cancer [...]
Vanderbilt-Ingram Cancer Center is committed to conducting innovative and high-impact basic, translational and clinical research with the greatest potential for making a difference for cancer patients, today and in the future. Here’s a sampling of work published in peer-reviewed journals by Cancer Center investigators in 2012-2013: Study identifies new mechanism for cancer development Bhuminder [...]
As its presence expands around the globe, Vanderbilt-Ingram Cancer Center (VICC) has not forgotten about its patients closer to home. New affiliation agreements at the state level are broadening the scope of health care delivery for Tennesseans and their neighbors. The Vanderbilt Health Affiliated Network (VHAN) is the largest provider-organized network of doctors, regional health [...]
An “undruggable” cancer-causing protein, 30 years of research and the national initiative that aims to finally make the connections
Prostate cancer survivors step into the spotlight to take outcomes research in a new direction.